FDA Approves First-in-Class Treatment for IBS-C
Ibsrela is a sodium/hydrogen exchanger 3 (NHE3) inhibitor.
Irritable Bowel Syndrome
Rifaximin Beneficial for Abdominal Pain Symptoms in Irritable Bowel Syndrome With Diarrhea
Researchers evaluated the response of rifaximin therapy in patients with IBS-D with abdominal pain symptoms.
Rifaximin May Improve Abdominal Pain Symptoms in IBS-D
A 2-week course of treatment with rifaximin for diarrhea-predominant irritable bowel syndrome was found to improve abdominal pain symptoms.
IBS-Associated Chronic Pain: Formulation of Core Diagnostic Criteria
Public-private partnership initiative develops core diagnostic criteria for abdominal, pelvic, and urogenital pain associated with irritable bowel syndrome.
FDA to Review Trulance for IBS With Constipation in Adults
The FDA has accepted the supplemental New Drug Application for Trulance for the treatment of irritable bowel syndrome with constipation.
Hypnotherapy for Pediatric IBS: Comparing Self-Administered, in-Office Therapy
The efficiency of self-administered hypnotherapy is equivalent to that of in-office hypnotherapy in relieving pediatric irritable bowel syndrome or functional abdominal pain.
Probiotics May Improve Symptoms of Recurrent Abdominal Pain in Children
Probiotics may alleviate pain in the short-term in children with recurrent abdominal pain.
Irritable Bowel Syndrome Medication Linked to Pancreatitis
The FDA is warning patients and healthcare professionals that Viberzi tablets should not be used in patients without a gallbladder due to an increased risk of developing serious pancreatitis
Upper Functional GI Disorders Often Overlap With IBS
Most frequent upper functional GI disorders in IBS were functional dyspepsia, belching disorders
Stress, the Microbiota and Visceral Pain
A high proportion of individuals with IBS have comorbid anxiety and depression affecting the HPA axis and microbiota.
Next post in AAPM 2015
